CN117224589A - Traditional Chinese medicine preparation for preventing Alzheimer disease as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine preparation for preventing Alzheimer disease as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN117224589A CN117224589A CN202311240611.9A CN202311240611A CN117224589A CN 117224589 A CN117224589 A CN 117224589A CN 202311240611 A CN202311240611 A CN 202311240611A CN 117224589 A CN117224589 A CN 117224589A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- preparation
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims description 38
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 241001060310 Styracaceae Species 0.000 claims abstract description 19
- 235000001361 Styrax officinalis Nutrition 0.000 claims abstract description 19
- 235000019382 gum benzoic Nutrition 0.000 claims abstract description 19
- 241000132012 Atractylodes Species 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 12
- 241000185686 Apocynum venetum Species 0.000 claims description 9
- 241000756943 Codonopsis Species 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- 241000722949 Apocynum Species 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241000007126 Codonopsis pilosula Species 0.000 abstract description 9
- 102000013498 tau Proteins Human genes 0.000 abstract description 7
- 108010026424 tau Proteins Proteins 0.000 abstract description 7
- 230000002776 aggregation Effects 0.000 abstract description 4
- 238000004220 aggregation Methods 0.000 abstract description 4
- 230000026731 phosphorylation Effects 0.000 abstract description 3
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 3
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 241000722948 Apocynum cannabinum Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 23
- 241000700159 Rattus Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 210000005013 brain tissue Anatomy 0.000 description 13
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 10
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- -1 campanumaea Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 241000132003 Atractylis Species 0.000 description 2
- 241000132011 Atractylodes lancea Species 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- IXQGCWUGDFDQMF-UHFFFAOYSA-N o-Hydroxyethylbenzene Natural products CCC1=CC=CC=C1O IXQGCWUGDFDQMF-UHFFFAOYSA-N 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- JNAODAVKYBPIAG-UHFFFAOYSA-N 1,4-diphenylbut-2-yn-1-one Chemical compound C=1C=CC=CC=1C(=O)C#CCC1=CC=CC=C1 JNAODAVKYBPIAG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QIRNGVVZBINFMX-UHFFFAOYSA-N 2-allylphenol Chemical compound OC1=CC=CC=C1CC=C QIRNGVVZBINFMX-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- OLLPXZHNCXACMM-CMDGGOBGSA-N Propyl cinnamate Chemical compound CCCOC(=O)\C=C\C1=CC=CC=C1 OLLPXZHNCXACMM-CMDGGOBGSA-N 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 231100000568 intoxicate Toxicity 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for preventing Alzheimer's disease, and belongs to the technical field of Alzheimer's disease prevention. The traditional Chinese medicine composition comprises, by weight, 5-10 parts of dogbane leaves, 3-9 parts of platycladi seeds, 4-11 parts of codonopsis pilosula, 2-7 parts of bighead atractylodes rhizome and 1-3 parts of storax. The traditional Chinese medicine composition can slow down aggregation of Abeta and phosphorylation of Tau protein in human bodies, thereby preventing occurrence of Alzheimer disease.
Description
Technical Field
The invention relates to the technical field of Alzheimer disease prevention, in particular to a traditional Chinese medicine preparation for preventing Alzheimer disease, a preparation method and application thereof.
Background
With the progress of society and the development of economy, the proportion of old population is increased, the society presents aging, the central nervous system degenerative disease becomes a major social problem affecting public health and life happiness of people in China, wherein Alzheimer's Disease (AD) is a common central nervous system degenerative disease, alzheimer's disease is characterized by reduced cognitive function and is characterized by dementia, typical pathological changes are senile plaques formed by beta-amyloid beta-protein (Abeta) precipitation and nerve fiber entanglement containing phosphorylated Tau protein (phosphorylated Tau pro-tein, p-Tau), abeta expression is increased to activate and proliferate astrocytes and finally cause neuronal damage and memory disorder.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine preparation for preventing Alzheimer disease, a preparation method and application thereof. Specifically, the method is realized by the following technology.
The invention provides a traditional Chinese medicine composition for preventing Alzheimer's disease, which is characterized by comprising, by weight, 5-10 parts of dogbane leaves, 3-9 parts of platycladi seeds, 4-11 parts of codonopsis pilosula, 2-7 parts of bighead atractylodes rhizome and 1-3 parts of storax.
The traditional Chinese medicine used in the invention has the following properties:
folium Apocyni Veneti: sweet and bitter in taste and cool in nature, has the effects of calming liver, soothing nerves, clearing heat, promoting diuresis, calming the nerves, resisting depression and protecting liver, and has a good effect of improving liver-yang dizziness, palpitation and insomnia; mainly contains flavonoids (hyperin, rutin, kaempferide, quercetin, etc.), organic acids (fumaric acid, succinic acid, chlorogenic acid, etc.), tannins, anthraquinone, amino acids, etc. Semen Platycladi: sweet in taste, flat in nature and moist in texture, has the effects of nourishing yin and blood, nourishing heart and soothing nerves, relaxing bowel and stopping sweat, and has good effects of improving dysphoria and insomnia caused by yin and blood deficiency and constipation caused by intestinal dryness; mainly contains cypress wood alcohol, sitosterol, diterpenoid components, fatty oil, a small amount of volatile oil, saponin, vitamin A, protein and the like. Radix codonopsis pilosulae: sweet in taste and flat in nature, has the effects of tonifying qi, promoting fluid production and nourishing blood, and is sweet and flat, not dry and greasy; mainly contains radix Codonopsis, glucose, inulin, polysaccharide, campanumaea, volatile oil, flavonoids, phytosterol, microelements, etc. Storax: the aromatic oil mainly contains volatile oil components such as cinnamic acid, a-and beta-pinene, myrcene, camphene, limonene, p-cymene, terpinene, linalool, terpineol-4-ol, a-terpineol, cinnamaldehyde, trans-methyl cinnamate, ethylphenol, allylphenol, n-propyl cinnamate, beta-phenylpropionic acid, 1-benzoyl-3-phenylpropyne, dichloro coumarone, epoxycinnamyl cinnamate, cis-cinnamic acid cinnamyl intoxicate and the like. White atractylodes rhizome: bitter taste, sweet taste, warm nature, and effects of invigorating spleen, invigorating qi, eliminating dampness, promoting diuresis, relieving sweat, consolidating superficial resistance, strengthening body resistance, and removing water dampness, and contains volatile oils such as atractylone, atractylol, atractylther, du Songnao, atractylis, and fat, and also contains components such as atractylis ovata internal lipid, fructose, inulin, atractylis polysaccharide, various amino acids, atractylis ovata triol, and vitamin A.
Typical pathological changes in AD are aβ precipitation aggregation and p-Tau containing neurofibrillary tangles, where aβ is the product of sequential cleavage of amyloid precursor protein (amyloid precursor protein, APP) by β -secretase, bace1 and γ -secretase; in the prior studies, the most likely mechanism of p-Tau-containing neurofibrillary tangles is that glycogen synthase kinase-3 beta activity is activated with increasing aβ, an enzyme that can further catalyze the hyperphosphorylation of the Tau protein. The traditional Chinese medicine extract is a preparation prepared from a traditional Chinese medicine composition obtained by adopting a modern new technology of traditional Chinese medicines and based on the pharmacological screening of modern traditional Chinese medicines according to the traditional Chinese medicine theory, and the medicines are mutually phase-matched, so that the traditional Chinese medicine extract finally prepared has the effects of tonifying qi and blood, soothing liver and relieving depression, activating spleen and inducing resuscitation, and securing essence and arresting sweating, and can slow down the aggregation of Abeta and the phosphorylation of Tau protein in a human body, thereby preventing the occurrence of Alzheimer disease.
Preferably, the traditional Chinese medicine composition comprises, by weight, 9 parts of apocynum venetum leaves, 5 parts of platycladi seeds, 8 parts of codonopsis pilosula, 6 parts of bighead atractylodes rhizome and 2 parts of storax.
The second aspect of the invention provides a preparation method of a pharmaceutical composition for preventing Alzheimer's disease, which is carried out by taking the traditional Chinese medicine composition as a raw material.
Preferably, the preparation method of the medicinal components comprises pulverizing and mixing the raw materials of the Chinese medicinal composition.
Preferably, the preparation method of the above-mentioned pharmaceutical ingredient comprises the following steps:
uniformly mixing folium Apocyni Veneti, semen Platycladi, radix Codonopsis, atractylodis rhizoma and storax to obtain a Chinese medicinal mixture, adding water for the first time, soaking, decocting for the first time, and filtering to obtain a first decoction;
adding water into the Chinese medicinal mixture for the second time, decocting for the second time, and filtering to obtain a second decoction;
and uniformly mixing the first decoction and the second decoction to obtain the traditional Chinese medicine extract.
Preferably, the water amount added for the first time is 2-4 times of the total mass of the traditional Chinese medicine mixture, and the time for the first time is 1.5-2 hours.
Preferably, the soaking time is 30-45min.
Preferably, the water amount of the second water adding is 1.5-2 times of the total mass of the traditional Chinese medicine mixture, and the time of the second decoction is 1-1.5h.
The third aspect of the invention provides a traditional Chinese medicine preparation for preventing Alzheimer disease, which comprises the medicinal components prepared by taking the traditional Chinese medicine composition as raw materials or the medicinal components prepared by the preparation method.
Preferably, the Chinese medicinal preparation can be any one of pills, capsules, granules, powder, tablets, soft extract, syrup or oral liquid. Pharmaceutically acceptable auxiliary materials can be selectively added according to the requirement of the dosage form, or auxiliary materials can be not added.
The fourth aspect of the invention provides an application of any one of the traditional Chinese medicine composition described in the first aspect of the invention, or the pharmaceutical ingredient prepared by any one of the preparation methods described in the second aspect of the invention, or any one of the traditional Chinese medicine preparation described in the third aspect of the invention in preparing medicines, health care products or functional foods for preventing Alzheimer's disease.
Compared with the prior art, the invention has the following advantages:
under the interaction of the raw materials, the traditional Chinese medicine composition has the effects of tonifying qi and blood, soothing liver and relieving depression, activating spleen and inducing resuscitation, and stopping nocturnal emission and perspiration, and can slow down the aggregation of Abeta and the phosphorylation of Tau protein in a human body, thereby preventing the occurrence of Alzheimer disease.
Detailed Description
In order to further illustrate the present invention, the following detailed description of the technical solutions provided by the present invention is provided in connection with the examples, but they should not be construed as limiting the scope of the present invention.
The invention relates to a traditional Chinese medicine preparation for preventing Alzheimer disease, which comprises, by weight, 5-10 parts of dogbane leaves, 3-9 parts of platycladi seeds, 4-11 parts of radix codonopsis, 2-7 parts of bighead atractylodes rhizome and 1-3 parts of storax.
The components are proportioned according to parts by weight, and can be increased or reduced according to corresponding proportion during production, for example, large-scale production can be carried out in kilograms or tons, small-scale production can be carried out in grams, and the weight can be increased or reduced, but the proportion of the weight proportion of the raw materials among the components is unchanged.
The Chinese medicinal preparation of the invention can be any pharmaceutically acceptable dosage form, and the dosage forms comprise: pill, capsule, granule, powder, tablet, soft extract, syrup or oral liquid.
The Chinese medicinal preparation of the present invention, which is orally administered, may contain usual excipients such as binders, fillers, diluents, tabletting agents, lubricants, disintegrants, colorants, flavoring agents and wetting agents, and if necessary, the tablets may be coated. The oral liquid preparation may be in the form of, for example, an aqueous or oily suspension, solution, emulsion or syrup, or may be a dry product which may be formulated with water or other suitable carrier prior to use. Such liquid preparations may contain conventional additives such as suspending agents, for example gelatin, sorbitol, methylcellulose, hydroxyethylcellulose or carboxymethylcellulose; emulsifying agents, for example lecithin, sorbitan-oleate or acacia; non-aqueous carriers (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters of glycerol, propylene glycol or ethyl alcohol; preservatives, for example methyl or propyl parahydroxybenzoate or sorbic acid, and may, if desired, contain conventional flavourings or colourants. The addition of the above excipients, coatings, additives, emulsifiers, non-aqueous carriers, preservatives, fragrances or colorants does not affect the effect of the present invention.
The invention relates to a preparation method of a traditional Chinese medicine extract for preventing Alzheimer disease, which comprises the following steps:
uniformly mixing folium Apocyni Veneti, semen Platycladi, radix Codonopsis, atractylodis rhizoma and storax to obtain a Chinese medicinal mixture, adding water for the first time, soaking, decocting for the first time, and filtering to obtain a first decoction;
adding water into the Chinese medicinal mixture for the second time, decocting for the second time, and filtering to obtain a second decoction;
and uniformly mixing the first decoction and the second decoction to obtain the traditional Chinese medicine extract.
Optionally, the water amount added for the first time is 2-4 times of the total mass of the traditional Chinese medicine mixture, and the time for the first time is 1.5-2 hours.
Optionally, the soaking time is 30-45min.
Optionally, the water amount of the second water adding is 1.5-2 times of the total mass of the traditional Chinese medicine mixture, and the time of the second decoction is 1-1.5h.
The prepared traditional Chinese medicine extract can be used for preparing the traditional Chinese medicine preparation. The preparation method of the pills, capsules, granules, powder, tablets, soft extract, syrup and oral liquid is a conventional technical method in the traditional Chinese medicine industry.
The following description of the present invention will be made clearly and fully, and it is apparent that the embodiments described are only some, but not all, of the embodiments of the present invention. All other embodiments, which can be made by one of ordinary skill in the art without undue burden on the person of ordinary skill in the art based on embodiments of the present invention, are within the scope of the present invention.
Example 1
The traditional Chinese medicine extract for preventing Alzheimer disease comprises, by weight, 9 parts of dogbane leaves, 5 parts of platycladi seeds, 8 parts of radix codonopsis, 6 parts of bighead atractylodes rhizome and 2 parts of storax.
The preparation method of the traditional Chinese medicine extract comprises the following steps:
uniformly mixing 9 parts of apocynum venetum leaves, 5 parts of platycladi seeds, 8 parts of codonopsis pilosula, 6 parts of bighead atractylodes rhizome and 2 parts of storax to obtain a traditional Chinese medicine mixture, adding water according to 3 times of the total mass of the traditional Chinese medicine mixture, soaking for 40min, decocting for 2h, and filtering to obtain a first decoction;
adding water into the traditional Chinese medicine mixture according to 2 times of the total mass of the traditional Chinese medicine mixture, decocting for 1h, and filtering to obtain a second decoction;
and uniformly mixing the first decoction and the second decoction to obtain the traditional Chinese medicine extract.
Example 2
The traditional Chinese medicine extract for preventing Alzheimer disease comprises, by weight, 10 parts of dogbane leaves, 9 parts of platycladi seeds, 4 parts of codonopsis pilosula, 7 parts of bighead atractylodes rhizome and 1 part of storax.
The preparation method of the traditional Chinese medicine extract comprises the following steps:
uniformly mixing 10 parts of apocynum venetum leaves, 9 parts of platycladi seeds, 4 parts of codonopsis pilosula, 7 parts of bighead atractylodes rhizome and 1 part of storax to obtain a traditional Chinese medicine mixture, adding water according to 4 times of the total mass of the traditional Chinese medicine mixture, soaking for 45min, decocting for 1.5h, and filtering to obtain a first decoction;
adding water into the traditional Chinese medicine mixture according to 2 times of the total mass of the traditional Chinese medicine mixture, decocting for 1.5h, and filtering to obtain a second decoction;
and uniformly mixing the first decoction and the second decoction to obtain the traditional Chinese medicine extract.
Example 3
The traditional Chinese medicine extract for preventing Alzheimer disease comprises, by weight, 5 parts of dogbane leaves, 3 parts of platycladi seeds, 11 parts of codonopsis pilosula, 2 parts of bighead atractylodes rhizome and 3 parts of storax.
The preparation method of the traditional Chinese medicine extract comprises the following steps:
uniformly mixing 5 parts of apocynum venetum leaves, 3 parts of platycladi seeds, 11 parts of codonopsis pilosula, 2 parts of bighead atractylodes rhizome and 3 parts of storax to obtain a traditional Chinese medicine mixture, adding water according to 2 times of the total mass of the traditional Chinese medicine mixture, soaking for 30min, decocting for 1.5h, and filtering to obtain a first decoction;
adding water into the traditional Chinese medicine mixture according to 1.5 times of the total mass of the traditional Chinese medicine mixture, decocting for 1.5 hours, and filtering to obtain a second decoction;
and uniformly mixing the first decoction and the second decoction to obtain the traditional Chinese medicine extract.
Comparative example 1
This comparative example is substantially the same as example 1 except that the leaves of Apocynum venetum are replaced with equal parts by weight of Codonopsis pilosula.
Comparative example 2
This comparative example is essentially the same as example 1, except that the dangshen is replaced with an equal weight fraction of dogbane leaf.
Comparative example 3
The comparative example is basically the same as example 1, except that the apocynum venetum leaf and the dangshen are mixed and extracted to obtain a mixed extract I, the platycladi seed, the bighead atractylodes rhizome and the storax are mixed and extracted to obtain a mixed extract II, and the mixed extract I and the mixed extract II are uniformly mixed to obtain the traditional Chinese medicine extract of the comparative example.
Test examples
(1) The Chinese medicinal extracts prepared in examples 1 to 3 and comparative examples 1 to 3 were subjected to a test for the preventive effect on AD.
Experimental animals: 80 male Wistar rats (150-180 g in body mass) without specific pathogen were purchased randomly. Before the experiment starts, the rats are placed at room temperature (22+/-1) DEG C and humidity (60+/-5)%, and are subjected to light and shade circulation for 12 hours, and the rats are fed in a clean, tidy and well ventilated animal house in an adaptive manner for 1 week.
Experimental reagent: examples 1-3 and comparative examples 1-3, physiological saline, D-galactose (D-gal), aluminum chloride (AlCl) 3 ). D-gal and AlCl 3 All are dissolved by normal saline.
Grouping and administration of rats: 80 rats were randomly divided into 8 groups of 10 rats each, corresponding to examples 1-3 and comparative examples 1-3, AD model group and blank group, respectively; wherein each group was dosed as follows:
AD model group: daily injections of 60mg/kg BW D-gal and 10mg/kg BW AlCl were administered by intraperitoneal injection 3 And continuously irrigating the stomach for 6 weeks by using normal saline matched with the equivalent volumes of other groups;
example 1: daily injections of 60mg/kg BW D-gal and 10mg/kg BW AlCl were administered by intraperitoneal injection 3 And the traditional Chinese medicine extract in the example 1 of 5 mg/kg-BW was used for continuous gastric lavage for 6 weeks; examples 2 to 3 and comparative examples 1 to 3 were treated in the same manner as in example 1;
blank control group: physiological saline matched to the equivalent volumes of the other groups was administered daily by intraperitoneal injection and lavage for 6 consecutive weeks.
(2) Biochemical index determination
After fasted 24h and free drinking water treatment, 10% chloral hydrate is injected into the abdominal cavity to anesthetize the brain tissues of the rats, the brain tissues of the rats are rapidly cut off on ice, the brain tissues (g) of the rats are mixed with physiological saline (mL) pre-cooled at 4 ℃ in advance according to the proportion of 1:9, grinding beads are added, a refiner is used for fully homogenizing, and 10% brain homogenate supernatant is obtained by centrifugation for 10min at 4 ℃ and 2500r/min and is used for measuring the content of Abeta and p-Tau in the brain tissues. The measurement results are shown in Table 1.
TABLE 1 Abeta and p-Tau content in rat brain tissues of each group
| Group of | Aβ(ng/gprotein) | p-Tau(ng/gprotein) |
| AD model group | 355.46±48.03 | 88.37 |
| Example 1 | 258.31±50.14 | 61.45 |
| Example 2 | 261.33±44.31 | 63.61 |
| Example 3 | 260.12±52.23 | 65.22 |
| Comparative example 1 | 289.64±39.99 | 79.47 |
| Comparative example 2 | 292.11±49.08 | 78.52 |
| Comparative example 3 | 268.69±51.66 | 74.11 |
| Blank control group | 188.34±31.35 | 44.48 |
As can be seen from Table 1, compared with the AD model group, the contents of Abeta and p-Tau in the brain tissue of the rat in examples 1-3 are obviously reduced, which indicates that the Chinese medicinal extract can reduce the contents of Abeta and p-Tau in the brain tissue of the rat, thereby achieving the effect of preventing Alzheimer's disease; the traditional Chinese medicine extract provided by the invention can slow down Abeta aggregation and Tau protein phosphorylation in rat brain by inhibiting APP increase and glycogen synthase kinase-3 beta activity.
The amounts of aβ and p-Tau in the brain tissues of the rats of comparative examples 1-2 were somewhat reduced, as compared to the AD model group; however, the amounts of aβ and p-Tau in the brain tissues of rats in comparative examples 1-2 were still higher than in example 1, because apocynum leaves were not used in comparative example 1 and dangshen were not used in comparative example 2, and thus the reduction effect of the extract of the traditional Chinese medicine prepared in comparative examples 1 and 2 on the amounts of aβ and p-Tau in the brain tissues of rats was poor.
The contents of Abeta and p-Tau in the brain tissue of the rat of comparative example 3 were further reduced as compared with comparative examples 1-2; however, the amounts of aβ and p-Tau in the brain tissues of rats in comparative examples 1-2 were still higher than in example 1, probably because the effect of the prepared extract of traditional Chinese medicine on lowering the amounts of aβ and p-Tau in the brain tissues of rats was slightly inferior because the extract of traditional Chinese medicine prepared in comparative example 3 was prepared by mixing and decocting the leaves of apocynum venetum and the dangshen, and the semen Platycladi, the white atractylodes rhizome and storax, i.e., the leaves of apocynum venetum, the dangshen, the semen Platycladi, the white atractylodes rhizome and the storax were not mixed and decocted together.
The above detailed description describes in detail the practice of the invention, but the invention is not limited to the specific details of the above embodiments. Many simple modifications and variations of the technical solution of the present invention are possible within the scope of the claims and technical idea of the present invention, which simple modifications are all within the scope of the present invention.
Claims (10)
1. The traditional Chinese medicine composition for preventing Alzheimer disease is characterized by comprising, by weight, 5-10 parts of dogbane leaves, 3-9 parts of platycladi seeds, 4-11 parts of radix codonopsis, 2-7 parts of bighead atractylodes rhizome and 1-3 parts of storax.
2. The traditional Chinese medicine composition for preventing the Alzheimer's disease according to claim 1, wherein the traditional Chinese medicine composition comprises, by weight, 9 parts of apocynum venetum leaves, 5 parts of platycladi seeds, 8 parts of radix codonopsis, 6 parts of bighead atractylodes rhizome and 2 parts of storax.
3. A preparation method of a pharmaceutical composition for preventing Alzheimer's disease, which is characterized by taking the traditional Chinese medicine composition as defined in any one of claims 1-2 as a raw material.
4. The preparation method of claim 3, wherein the raw materials are crushed and mixed uniformly.
5. A method of preparation according to claim 3, comprising the steps of:
uniformly mixing folium Apocyni Veneti, semen Platycladi, radix Codonopsis, atractylodis rhizoma and storax to obtain a Chinese medicinal mixture, adding water for the first time, soaking, decocting for the first time, and filtering to obtain a first decoction;
adding water into the traditional Chinese medicine mixture for the second time, decocting for the second time, and filtering to obtain a second decoction;
and uniformly mixing the first decoction and the second decoction to obtain the traditional Chinese medicine extract.
6. The preparation method according to claim 5, wherein the amount of water added for the first time is 2-4 times the total mass of the Chinese medicinal mixture, and the time for the first time is 1.5-2 hours.
7. The method according to claim 5, wherein the soaking time is 30-45min.
8. The preparation method according to claim 5, wherein the amount of water added for the second time is 1.5-2 times the total mass of the Chinese medicinal mixture, and the time for the second time is 1-1.5 hours.
9. A Chinese medicinal preparation for preventing alzheimer's disease, which is characterized by comprising a medicinal component prepared by using the Chinese medicinal composition according to any one of claims 1-2 as a raw material or a medicinal component prepared by using the preparation method according to any one of claims 3-8.
10. Use of a traditional Chinese medicine composition according to any one of claims 1-2, or a pharmaceutical ingredient prepared by a preparation method according to any one of claims 3-8, or a traditional Chinese medicine preparation according to claim 9 in the preparation of a medicament, a health product or a functional food for preventing alzheimer's disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311240611.9A CN117224589A (en) | 2023-09-25 | 2023-09-25 | Traditional Chinese medicine preparation for preventing Alzheimer disease as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311240611.9A CN117224589A (en) | 2023-09-25 | 2023-09-25 | Traditional Chinese medicine preparation for preventing Alzheimer disease as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117224589A true CN117224589A (en) | 2023-12-15 |
Family
ID=89085802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311240611.9A Pending CN117224589A (en) | 2023-09-25 | 2023-09-25 | Traditional Chinese medicine preparation for preventing Alzheimer disease as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117224589A (en) |
-
2023
- 2023-09-25 CN CN202311240611.9A patent/CN117224589A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017143798A1 (en) | Health preserving and kidney tonifying okra wine and preparation method therefor | |
| US20100112107A1 (en) | Plant extract compositions for affecting sleep | |
| KR102121153B1 (en) | Dietary herbal composition, dietary herbal medicine pill comprising the same and method for manufacturing thereof | |
| CN101543248B (en) | A cold tea especially suitable for 'three high and one acid' population and method for preparing same | |
| JP6773821B2 (en) | A composition for the prevention, amelioration or treatment of degenerative neurological diseases containing a mixed extract of mulberry and bukuryo skin. | |
| KR101826737B1 (en) | A composition containing herbs extract, and manufacturing method of the same | |
| KR102192573B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
| CN103349121A (en) | Hyperglycemia-hyperlipidemia-hypertension relieving health protection tea and preparation method thereof | |
| KR102092509B1 (en) | Food composition for preventing and improving of dementia | |
| JP4516958B2 (en) | Anti-diabetic composition | |
| KR101045025B1 (en) | Pharmaceutical composition for preventing or treatment of asthma | |
| CN112107612A (en) | Traditional Chinese medicine composition for benefiting qi, nourishing blood, maintaining beauty and keeping young as well as preparation method and application thereof | |
| CN111135235A (en) | A composition for preventing and relieving acute alcoholism or alcoholic intoxication | |
| CN110538311A (en) | Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof | |
| CN105861252A (en) | Ganoderma lucidum health-care rice wine | |
| CN117224589A (en) | Traditional Chinese medicine preparation for preventing Alzheimer disease as well as preparation method and application thereof | |
| KR102222174B1 (en) | Pills using a concentrate of acori graminei rhizoma and a method of manufaturing the same | |
| KR20110082444A (en) | Compositions comprising sophora subprostrata extracts for inhibiting the activity of acetylcholinesterase | |
| KR20110101649A (en) | Composition for inducing sleep | |
| CN102846113A (en) | Mulberry leaf health care pillow core and preparation method thereof | |
| CN113368145A (en) | Traditional Chinese medicine composition and health-care food preparation for enhancing immunity | |
| KR20140010831A (en) | The improved composition for relieving hangovers and protecting a liver | |
| KR20050074732A (en) | Crude drug composition for treating or alleviating inflammatory disease | |
| KR101408405B1 (en) | COMPOSITION FOR IMPROVING SKIN DISEASE, COMPRISING Hovenia ducis AND SEED OF Allium tuberosum | |
| TW201632082A (en) | Preparation method of Chinese medicine healthcare beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |